Page 17 - Read Online

Genovesi et al. Vessel Plus 2021;5:50 https://dx.doi.org/10.20517/2574-1209.2021.67 Page 11 of 11

43. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-
chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging
2013;6:195-201. DOI PubMed PMC
44. Cappelli F, Gallini C, Di Mario C, et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of
transthyretin cardiac amyloidosis. J Nucl Cardiol 2019;26:497-504. DOI PubMed
45. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
DOI PubMed
46. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for
multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol
2019;26:2065-123. DOI PubMed
47. Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin
cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:1314-21. DOI PubMed
48. Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. (99m)Tc-DPD uptake reflects amyloid fibril composition in
hereditary transthyretin amyloidosis. Ups J Med Sci 2016;121:17-24. DOI PubMed PMC
49. Wakfie-Corieh CG, Ramos López N, Saiz-Pardo Sanz M, Pérez Castejón MJ, Vilacosta I. Not all heart uptakes on 99mTc-DPD
scintigraphy are amyloidosis: chloroquine-induced cardiomyopathy. Clin Nucl Med 2021;46:e188-9. DOI PubMed
50. Chimenti C, Alfarano M, Maestrini V, et al. False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic
cardiomyopathy. ESC Heart Fail 2021. DOI PubMed
51. Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications
for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016;25:413-7. DOI PubMed
52. Segall G, Delbeke D, Stabin MG, et al; SNM. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med
2010;51:1813-20. DOI PubMed
18
53. Trivieri MG, Dweck MR, Abgral R, et al. F-Sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol
2016;68:2712-4. DOI PubMed PMC
18
54. Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. Fluorine sodium fluoride positron emission tomography, a potential
biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol 2018;25:1559-67. DOI PubMed
55. Ng QKT, Sethi P, Saunders TA, Pampaloni MH, Flavell RR. Discordant findings on 18F-NaF and 99mTc-HDP bone scans in a patient
with ATTR cardiac amyloidosis. Clin Nucl Med 2018;43:e89-92. DOI PubMed
56. Zhang LX, Martineau P, Finnerty V, et al. Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-
pyrophosphate in cardiac amyloidosis. J Nucl Cardiol 2020. DOI PubMed